Adrenoleukodystrophy Epidemiology

DelveInsight's 'Adrenoleukodystrophy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Adrenoleukodystrophy Understanding

The DelveInsight Adrenoleukodystrophy epidemiology report gives a thorough understanding of the Adrenoleukodystrophy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adrenoleukodystrophy in the US, Europe, and Japan. The report covers the detailed information of the Adrenoleukodystrophy epidemiology scenario in seven major countries (US, EU5, and Japan).


Adrenoleukodystrophy Epidemiology Perspective by DelveInsight

The Adrenoleukodystrophy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Adrenoleukodystrophy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Adrenoleukodystrophy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Adrenoleukodystrophy Detailed Epidemiology Segmentation

The Adrenoleukodystrophy epidemiology covered in the report provides historical as well as forecasted Adrenoleukodystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Adrenoleukodystrophy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Adrenoleukodystrophy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Adrenoleukodystrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Adrenoleukodystrophy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Adrenoleukodystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy
  • The report provides the segmentation of the Adrenoleukodystrophy epidemiology


Report Highlights

  • 11-Year Forecast of Adrenoleukodystrophy epidemiology
  • 7MM Coverage
  • Total Cases of Adrenoleukodystrophy
  • Total Cases of Adrenoleukodystrophy according to segmentation
  • Diagnosed cases of Adrenoleukodystrophy


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adrenoleukodystrophy?
  • What are the key findings pertaining to the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Adrenoleukodystrophy?
  • What are the currently available treatments of Adrenoleukodystrophy?


Reasons to buy

  • The Adrenoleukodystrophy Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Adrenoleukodystrophy market
  • Quantify patient populations in the global Adrenoleukodystrophy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenoleukodystrophy therapeutics in each of the markets covered
  • Understand the magnitude of Adrenoleukodystrophy population by its epidemiology
  • The Adrenoleukodystrophy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

2.1. Total Epidemiology Share (%) Distribution of ALD in 2017

2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview

3.1. Introduction

3.2. Clinical aspects of ALD

3.3. Causes of ALD

3.4. Inheritance pattern of ALD

3.5. ALD-Symptoms

3.6. Pathogenesis and Pathophysiology of ALD

3.7. Diagnosis

3.7.1. ALD Newborn Screening

3.7.2. Tools for evaluating Cerebral ALD

3.7.3. Diagnostic algorithm

3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Epidemiology Methodology

4.3. KOL Views

4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States

5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States

5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States

5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology

6.1. Germany Epidemiology

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany

6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany

6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany

6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany

6.2. France Epidemiology

6.2.1. Assumptions and rationale

6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France

6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France

6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France

6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France

6.3. Italy Epidemiology

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy

6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy

6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy

6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy

6.4. Spain Epidemiology

6.4.1. Assumptions and Rationale

6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain

6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain

6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain

6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain

6.5. United Kingdom Epidemiology

6.5.1. Assumptions and Rationale

6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom

6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom

6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom

6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan

7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan

7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan

7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Table 1 ALD Phenotypes in Males

Table 2 Phenotype in Female ALD carriers

Table 3 The ALD Phenotypes

Table 4 MRI Severity Scale

Table 5 MRI Severity Rating

Table 6 Neurological Function Score (NFS Score)

Table 7 X-linked Adrenoleukodystrophy-Disability Rating Scale (ALD-DRS)

Table 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)

Table 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)

Table 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Table 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Table 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)

Table 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)

Table 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Table 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Table 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)

Table 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)

Table 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)

Table 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)

Table 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)

Table 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)

Table 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Table 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Table 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)

Table 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)

Table 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Table 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Table 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)

Table 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)

Table 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Table 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Table 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)

Table 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)

Table 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Table 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Table 36 Type-Specific Diagnosed Prevalence of ALD in Males Japan (2017–2030)

Figure 1 Evolution of Phenotypes in ALD

Figure 2 Clinical Spectrum of ALD

Figure 3 Inheritance spectrum of ALD

Figure 4 Pathogenesis of VLCFA

Figure 5 Principles of ALD 3-tier screening

Figure 6 Diagnostic algorithm for diagnosis of adrenoleukodystrophy

Figure 7 ALD Screening Decision Tree

Figure 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)

Figure 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)

Figure 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Figure 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Figure 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)

Figure 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)

Figure 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Figure 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Figure 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)

Figure 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)

Figure 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)

Figure 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)

Figure 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)

Figure 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)

Figure 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Figure 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Figure 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)

Figure 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)

Figure 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Figure 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Figure 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)

Figure 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)

Figure 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Figure 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Figure 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)

Figure 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)

Figure 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Figure 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Figure 36 Type-Specific Diagnosed Prevalence of ALD in Males in Japan (2017–2030)

  • Tags:
  • Adrenoleukodystrophy Epidemiology
  • Adrenoleukodystrophy
  • Adrenoleukodystrophy Pipeline
  • Adrenoleukodystrophy Companies
  • Adrenoleukodystrophy prevalent pop...
  • Adrenoleukodystrophy incident popu...
  • Adrenoleukodystrophy patients diag...
  • Adrenoleukodystrophy treatment alg...

Forward to Friend

Need A Quote